Sorted By Test Name - Mayo Medical Laboratories

FCLIN
80143
PCLLM
20437
Reference Values:
Class IgE kU/L Interpretation
0 Negative
1 0.35-0.69 Equivocal
2 0.70-3.49 Positive
3 3.50-17.4 Positive
4 17.5-49.9 Strongly positive
5 50.0-99.9 Strongly positive
6 > or =100 Strongly positive Reference values
apply to all ages.
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by
Laboratory Methods. 21st edition. Edited by McPherson RA, Pincus MR. WB Saunders, Publ, New York,
Chapter 53, Part VI, pp. 961-971, 2007
Clindamycin Level, BA
Reference Values:
Peak serum level (avg)
150 mg oral dose: 2.5 mcg/mL
Trough serum level (avg):
150 mg oral, 6 hrs: 5.4 mcg/mL
Peak serum level (avg)
300 mg IV, 3 hrs: 5.4 mcg/mL
Any undisclosed antimicrobials might affect the results.
Test Performed By: Focus Diagnostics, Inc.
5785 Corporate Ave.
Cypress, CA 90630-4750
CLL Monitoring, MRD Detection FLIP, see #60490
Clinical Information: Chronic lymphocytic leukemia (CLL) is a low-grade, B-cell neoplasm that is
the most common leukemia detected in the western world. It is a disease primarily of adults and may
present as a lymphocytosis, be detected as part of a lymphadenopathy evaluation, or be found incidentally
in an otherwise asymptomatic patient. The diagnosis of CLL is based on a combination of morphologic
features showing primarily small lymphoid cells with coarse chromatin and scant cytoplasm and an
immunophenotype of clonal B-cells with dim immunoglobulin, dim CD20, and coexpression of CD5 and
CD23. New therapeutic approaches in CLL have been increasingly successful with some patients showing
no or only very minimal residual disease (MRD) in their peripheral blood or bone marrow specimens
following a therapeutic course. Immunophenotyping studies are necessary as morphologic features are not
sufficient to detect MRD. The absence of MRD is an important prognostic indicator in these patients.
Useful For: Confirming the presence or absence of minimal residual disease in patients with known
chronic lymphocytic leukemia who are either post-chemotherapy or post-bone marrow transplantation
Interpretation: An interpretive report for presence or absence of minimal residual disease (MRD) for
chronic lymphocytic leukemia (CLL) is provided. Individuals without CLL should not have detectable
clonal B-cells in the peripheral blood or bone marrow. Patients who have detectable MRD by this assay
are considered to have residual CLL disease.
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 479